Micron Tech and Citigroup among market cap stock movers on Wednesday

Investing.com – Turkey stocks were higher after the close on Wednesday, as gains in the Leasing & Factoring, Wholesale & Retail Trade and Holdings & Investments sectors led shares higher.

At the close in Istanbul, the BIST 100 rose 0.44%.

The best performers of the session on the BIST 100 were Balsu Gida Sanayi ve Ticaret AS (IS:BALSU), which rose 9.92% or 1.70 points to trade at 18.83 at the close. Meanwhile, Dogal Enerji Kaynaklari Arastirma ve Uretim AS (IS:TRENJ) added 6.00% or 5.35 points to end at 94.50 and Oba Makarnacilik Sanayi ve Ticaret AS (IS:OBAMS) was up 4.47% or 0.31 points to 7.25 in late trade.

The worst performers of the session were Efor Yatırım Sanayi ve Ticaret A.Ş. (IS:EFOR), which fell 9.60% or 2.66 points to trade at 25.06 at the close. Batisoke Soke Cimento Sanayi TAS (IS:BSOKE) declined 9.21% or 1.64 points to end at 16.16 and Turk Altin Isletmeleri AS (IS:TRALT) was down 6.50% or 2.98 points to 42.88.

Falling stocks outnumbered advancing ones on the Istanbul Stock Exchange by 345 to 242 and 19 ended unchanged.

Shares in Dogal Enerji Kaynaklari Arastirma ve Uretim AS (IS:TRENJ) rose to all time highs; up 6.00% or 5.35 to 94.50.

Gold Futures for February delivery was down 0.21% or 9.55 to $4,496.15 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in February rose 0.10% or 0.06 to hit $58.44 a barrel, while the February Brent oil contract fell 0.10% or 0.06 to trade at $62.32 a barrel.

USD/TRY was up 0.08% to 42.85, while EUR/TRY fell 0.13% to 50.63.

The US Dollar Index Futures was up 0.01% at 97.63.

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock surged 61.6% Wednesday after the FDA approved YARTEMLEA, the first and only treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

The approval represents a significant milestone for Omeros as YARTEMLEA becomes the first FDA-approved therapy for this often-fatal transplant complication. The drug is indicated for both adults and children ages two years and older who develop TA-TMA, a condition that affects up to 56% of allogeneic transplant recipients.

Clinical data supporting the approval showed impressive efficacy, with complete response rates of 61% in the pivotal trial and 68% in the Expanded Access Program among evaluable patients. The 100-day survival rate from TA-TMA diagnosis was approximately 74% across studies, despite all patients meeting criteria for high-risk disease with poor prognosis.

YARTEMLEA works by selectively inhibiting MASP-2, the effector enzyme of the lectin pathway, blocking pathway activation while preserving other complement functions important for host defense.

"This approval is a long-awaited breakthrough in hematopoietic cell transplantation and TA-TMA care," stated Miguel-Angel Perales, M.D., Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center.

The company plans to launch YARTEMLEA in January 2026, with dedicated billing and reimbursement codes already in place. The YARTEMLEAssist patient support program is expected to be available in the first quarter of 2026.

Approximately 30,000 allogeneic transplants are performed annually in the U.S. and Europe. A marketing authorization application for YARTEMLEA is currently under review by the European Medicines Agency, with a decision expected in mid-2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- China continues to restrict rare earth elements needed by the US for domestic production of permanent magnets and other products, despite an October agreement between President Donald Trump and Chinese President Xi Jinping that was meant to lift such restrictions.

According to a report from Bloomberg, citing more than a dozen consumers, producers, government officials and trade experts, while China has increased deliveries of finished products, primarily permanent magnets, the US industry still cannot acquire the raw materials needed to manufacture these items domestically.

The ongoing supply limitations highlight persistent tensions in US-China relations following the October 30 truce reached in South Korea, where the US agreed to cut tariffs and China pledged to restore rare earth supplies. At that time, Trump characterized the agreement as the "de facto removal" of various Chinese restrictions.

By limiting deliveries of raw materials, China is effectively hindering US efforts to establish its own processing industry for rare earths, which are critical components in products ranging from consumer electronics to missile guidance systems. The Trump administration has prioritized developing domestic production capacity for permanent magnets and other rare earth products to reduce dependence on China, which has established a global monopoly in the sector over many years.

The sources discussing these ongoing restrictions asked not to be identified as they were speaking about matters that aren’t public.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – Morocco stocks were lower after the close on Wednesday, as losses in the Utilities, Banking and Mining sectors led shares lower.

At the close in Casablanca, the Moroccan All Shares declined 0.14%.

The best performers of the session on the Moroccan All Shares were SMI (CSE:SMI), which rose 7.42% or 280.00 points to trade at 4,055.00 at the close. Meanwhile, Lesieur Cristal (CSE:LES) added 6.67% or 20.00 points to end at 320.00 and Delta Holding S.A (CSE:DHO) was up 5.93% or 4.31 points to 77.00 in late trade.

The worst performers of the session were CDM (CSE:CDM), which fell 7.41% or 80.00 points to trade at 1,000.00 at the close. Aradei Capital SA (CSE:ARD) declined 4.12% or 18.50 points to end at 430.00 and Colorado (CSE:COL) was down 3.44% or 2.89 points to 81.01.

Falling stocks outnumbered advancing ones on the Casablanca Stock Exchange by 33 to 20 and 9 ended unchanged.

Shares in SMI (CSE:SMI) rose to 5-year highs; up 7.42% or 280.00 to 4,055.00. Shares in Aradei Capital SA (CSE:ARD) fell to 52-week lows; losing 4.12% or 18.50 to 430.00.

Crude oil for February delivery was up 0.36% or 0.21 to $58.59 a barrel. Elsewhere in commodities trading, Brent oil for delivery in February rose 0.18% or 0.11 to hit $62.49 a barrel, while the February Gold Futures contract fell 0.11% or 5.00 to trade at $4,500.70 a troy ounce.

EUR/MAD was unchanged 0.01% to 10.76, while USD/MAD unchanged 0.03% to 9.12.

The US Dollar Index Futures was up 0.02% at 97.63.

Investing.com -- Tokenized index infrastructure adoption is accelerating, and two industry executives say the next phase will be defined by institutional adoption, cryptographic verification, and the shift toward real-time settlement.

Following news earlier this year that the S&P 500 is now accessible onchain through Centrifuge’s Proof-of-Index framework, Stephanie Rowton, Director of U.S. Equities at S&P Dow Jones Indices, told Investing.com that they expect more financial institutions to explore real-world tokenized products.

“As adoption in tokenized index infrastructure accelerates, we see more traditional financial institutions exploring real world tokenized products and integrating digital assets into their wider digital strategy, rather than being treated as a siloed innovation,” Rowton commented.

As a result, Rowton anticipates institutional pilots scaling into production, with a broader industry focus on cross-chain interoperability and privacy tools. 

“This trend will be supported by increased regulatory clarity and a convergence in national frameworks,” she added.

Meanwhile, S&P Dow Jones Indices’ priority is ensuring that any on-chain product referencing the S&P 500 can be cryptographically validated. 

She described S&P DJI’s Proof of Index system as publishing the official S&P 500 data “via a cryptographic hash, akin to a ‘digital fingerprint’,” which acts as a tamper-proof commitment to the true index state. 

This is said to allow licensed clients to confirm tracking accuracy “without disclosing their positions.”

Centrifuge’s Chief Strategy and Growth Officer, Anil Sood, stated that tokenized index products do not change investor exposure but modernise the infrastructure. 

“Ownership, settlement, and verification move onto a public blockchain,” he told Investing.com. Traditional ETF rails, he added, are “fragmented, slow, and opaque at the data layer.”

Sood, who joined Centrifuge in February, feels that the remaining hurdles for institutional adoption are mainly organisational rather than technological, citing internal risk policies, custody readiness and regulatory classification. 

“The infrastructure itself is no longer the blocker; it’s the institutional comfort level,” he stated. However, this is said to be changing, with Sood highlighting “the recent no action letter the DTC received from the SEC on tokenized assets.”

Demand for real-time settlement is expected to grow as firms pilot on-chain products. 

According to Sood, T+0 settlement is “increasingly becoming an operational requirement for certain flows,” particularly for market makers and systematic funds seeking efficiency and intraday collateral mobility.

Even so, “institutions don’t necessarily articulate it as ‘T+0’; they articulate it as the need for atomic, deterministic settlement and real-time collateral mobility. Tokenized index exposures inherently provide that capability,” he commented.

Sood concluded: “Once institutions experience intraday or instant settlement through pilots or tokenized products, the efficiency gain is obvious. We’re seeing growing demand, particularly from market makers, treasury desks, and systematic funds that want exposure without the friction of legacy market plumbing.”